Realm Therapeutics PLC Presentation at BIO CEO & Investor Conference

TIDMRLM

Realm Therapeutics PLC

13 February 2017

Realm Therapeutics plc

("Realm Therapeutics", "Realm" or the "Company")

Realm Therapeutics to present at BIO CEO & Investor Conference

13 February 2017 - Realm Therapeutics plc (AIM: RLM), an emerging specialty biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, is pleased to announce that Alex Martin, CEO, will be presenting at the BIO CEO & Investor Conference on Tuesday, February 14 (1:30 pm EST) at The Waldorf Astoria hotel in New York City.

Mr. Martin will review the Company's two drug development programs - PR022 for Atopic Dermatitis and PR013 for Allergic Conjunctivitis. The Company announced the submission of its first Investigational New Drug (IND) application for PR022 in January and is on track to submit an IND for PR013 in Q3.

Enquiries:

 
                                         +44 (0) 20 3727 
 Realm Therapeutics plc                   1000 
 Alex Martin, Chief Executive Officer 
 Marella Thorell, Chief Financial 
  Officer and Chief Operating Officer 
 
                                         +44 (0) 20 3727 
 FTI Consulting                           1000 
 Simon Conway / Mo Noonan 
 
 N+1 Singer (Nominated Adviser and       +44 (0) 20 7496 
  Broker)                                 3000 
 Aubrey Powell / Lauren Kettle

About Realm Therapeutics

Realm Therapeutics is an emerging specialty biopharmaceutical company focused on developing novel immunomodulatory therapies to protect and improve the lives of adults and children. The Company has initiated drug development programmes, based on its proprietary hypochlorous acid technology at high concentrations. The Company believes its formulations have novel immunomodulatory activity with potential application for the treatment of diseases in a number of therapeutic areas including Dermatology and Ophthalmology.

Forward looking statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRASFSFWSFWSEFE

(END) Dow Jones Newswires

February 13, 2017 02:00 ET (07:00 GMT)

Puricore (LSE:PURI)
Historical Stock Chart
From Apr 2024 to May 2024